After hearing that there was nothing anyone could do to help us or save Brad's life, Brad had a dream that told him to a specific clinical trial number in a packet he had received. When we looked at that treatment, it was Monoclonal Antibodies at Duke University. We contacted Dr. Henry Friedman and he returned our call that night at 11pm. By the following week, Brad was at Duke having the procedure. It gave him nine months of tumor free time and a fantastic quality of life. The friends we have made at Duke in the doctors, nurses etc was unbelievable. "At Duke there is Hope"! The people at Duke really cared about our family and continued to provide Brad with "weapons" with which to fight. He tried over 7 different chemotherapies. We truly believe that Duke's Brain Tumor Center is made up of the people it takes to find the CURE .. We also would like to recognize the staff at the Department of Neurosurgery at the University of Pennsylvania. They are wonderful and are taking very big steps to educate and assist patients and their families. Both Penn and Duke are integral parts in all our fundraising efforts and we are truly grateful to have these wonderful human beings working to find a cure. We are extremely grateful to have worked with UCLA and their Department of Neurosurgery. They are compassionate and committed to finding a cure for brain tumors.

Therefore our Scientific Advisory Board is made up of:

Darell D. Bigner, M.D., Ph.D.
Research Professor of Pathology The National Institute of Neurologic Disorders and Stroke Specialized Center of Research (SRC) on Malignant Human Gliomas, Medulloblastomas, and Metastases to the Central Nervous System at Duke University Medical Center and is intimately wedded to the Clinical Program, assuring rapid translation of the most recent and exciting laboratory discoveries to the clinic.

Henry S. Friedman, M.D.
Professor of Neuro Oncology is an internationally recognized neuro-oncologist with a career-long interest in the treatment of children and adults with brain and spinal cord tumors, and has written hundreds of articles on both the clinical and laboratory investigation of these neoplasms. He is head of the Pediatric Oncology Group Brain Tumor Committee and the Laboratory of Medical/Pediatric Neuro-Oncology at Duke University Medical Center, and is an Associate Chief of the Preuss Laboratory for Brain Tumor Research.

Allan Friedman, M.D.
Chief, Division of Neurosurgery is an internationally recognized tumor and vascular neurosurgeon. He has a career-long interest in neuro-oncology, is responsible for over ninety percent of all tumor resections and biopsies conducted at Duke, and has written hundreds of articles on the neurosurgical management of brain tumors and vascular lesions. He is also head of the Laboratory of Neurosurgical Oncology and an associate chief of the Preuss Laboratory for Brain Tumor Research.

M. Sean Grady M.D.
Professor of Neurosurgery Dr. Grady was appointed the Charles Harrison Frazier Professor & Chairman of the Department of Neurosurgery at the University of Pennsylvania School of Medicine.

Linda M. Liau, M.D., Ph.D.
Professor of Neurosurgery. Dr.. Liau is the Director of the UCLA Brain Tumor Program at the UCLA Department of Neurosurgery & Jonsson Comprehensive Cancer Center. Dr. Liau and her team are conducting extensive brain tumor research including translational experimental therapeutics of cell-based therapies for brain tumors and characterization of molecular targets involved in brain tumor pathogenesis and progression. She has published dozens of peer-reviewed research articles along with several book chapters and a textbook entitled Brain Tumor Immunotherapy (Humana Press, 2001). She is Editor-in-Chief of the Journal of Neuro-Oncology.